Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.47 |
| ▸ | LGMN | Q99538 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24195918 | 0.86 | F10 (0.48) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL19178457 | 0.86 | F10 (0.51) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL1028503 | 0.86 | F10 (0.48) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL2996200 | 0.86 | PTGS2 (0.50) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31347248 | 0.86 | F10 (0.48) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL15330927 | 0.83 | F10 (0.46) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL16404812 | 0.82 | F10 (0.45) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL25033227 | 0.82 | PTGS2 (0.46) | F10PTGS2 | |
| SCHEMBL5624892 | 0.82 | F10 (0.45) | F10PTGS2LGMNPIK3CDPIK3CA | |
| SCHEMBL3551807 | 0.82 | PIK3CD (0.50) | F10PTGS2LGMNPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2454253-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006567-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006567-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | F10 4132/4885PTGS2 735/4885LGMN 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.